UPDATE 3-US experts urge stronger limits for some pain drugs

* Panel urges ban on some prescription acetaminophen drugs

* FDA advisers seek lower nonprescription doses

* Non-prescription industry disputes recommendations

* Agency to weigh advice, make final decisions (Recasts; adds industry, FDA comments, background)

By Susan Heavey

ADELPHI, Md., June 30 (Reuters) - A U.S. advisory panel on Tuesday called for greater restrictions on the widely-used pain reliever acetaminophen, even recommending banning some medications that contain it, in a bid to prevent potentially fatal overdoses.

The Food and Drug Administration panel of outside experts, said the agency should take steps to curb the public's exposure to acetaminophen in both over-the-counter and prescription products that include the ingredient.

"I think we have to send the message that there are problems with this medication," Winifred Landis, a pharmacist from Indiana on the panel, told a two-day public meeting to discuss possible FDA action.

Overdoses of acetaminophen, perhaps best known as Johnson & Johnson's (JNJ.N) Tylenol, have long been known to cause liver failure and even death. But FDA officials are concerned current warnings are not heeded by consumers and are looking for new ways to reduce the number of overdoses.

Overall, such painkillers are safe when used as directed and liver damage is rarely seen, the agency said. But acetaminophen is the leading cause of acute liver failure in the 1,600 cases seen each year in the United States, according to a 2007 Centers for Disease Control and Prevention estimate.

The problem is that consumers sometimes take too much of the drug either by ingesting the wrong dose or unknowingly taking it via the growing number of products such as cough and cold medicines that contain acetaminophen, the FDA said.

The advisers urged a ban on prescription painkillers that include acetaminophen, such as Abbott Laboratories' (ABT.N) Vicodin and Endo Pharmaceuticals' (ENDP.O) Percocet -- two drugs that combine acetaminophen with powerful opioids.

If the agency decides against a recall, panelists said it should at least require a strong "black-box" warning on such combination products, also made by Watson Pharmaceuticals Inc (WPI.N) and Covidien Plc's (COV.N) Mallinckrodt unit.

"This is clearly the biggest cause of overdose problems," said panelist Dr. Marie Griffin, a preventive medicine professor at Vanderbilt University Medical Center. Griffin and other panelists said patients were often not aware that the powerful drugs even contained acetaminophen.

Abbott spokeswoman Elizabeth Hoff said the company would follow the agency's final decision. Other companies could not immediately be reached for comment.

LOWER DOSES